Difference between revisions of "Axicabtagene ciloleucel (Yescarta)"
Jump to navigation
Jump to search
m |
m |
||
Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
+ | *[[Follicular lymphoma]] | ||
*[[High-grade B-cell lymphoma]] | *[[High-grade B-cell lymphoma]] | ||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
Line 10: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*10/18/2017: Granted initial FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], [[Primary mediastinal B-cell lymphoma|primary mediastinal large B-cell lymphoma]], [[high-grade B-cell lymphoma]], and [[Transformed lymphoma|DLBCL arising from follicular lymphoma]]. NOT indicated for the treatment of patients with primary central nervous system lymphoma. | *10/18/2017: Granted initial FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], [[Primary mediastinal B-cell lymphoma|primary mediastinal large B-cell lymphoma]], [[high-grade B-cell lymphoma]], and [[Transformed lymphoma|DLBCL arising from follicular lymphoma]]. NOT indicated for the treatment of patients with primary central nervous system lymphoma. | ||
+ | *3/5/2021: Granted accelerated approval for adult patients with relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] after two or more lines of systemic therapy. | ||
==Also known as== | ==Also known as== | ||
Line 20: | Line 22: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
+ | [[Category:Follicular lymphoma medications]] | ||
+ | [[Category:High-grade B-cell lymphoma mdedications]] | ||
[[Category:Primary mediastinal B-cell lymphoma medications]] | [[Category:Primary mediastinal B-cell lymphoma medications]] | ||
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] |
Revision as of 18:21, 8 March 2021
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells.
Link to REMS
Diseases for which it is used
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- High-grade B-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Transformed lymphoma
History of changes in FDA indication
- 10/18/2017: Granted initial FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. NOT indicated for the treatment of patients with primary central nervous system lymphoma.
- 3/5/2021: Granted accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Also known as
- Code name: KTE-C19
- Generic names: Axicel, Axi-cel
- Brand name: Yescarta